Lamivudine Teva Pharma B.V. (Lamivudine)

Lamivudine is taken up by cells and phosphorylated to its active triphosphate form. This active metabolite mimics natural nucleosides and is incorporated into viral DNA by reverse transcriptase, causing chain termination and halting viral replication.

The dose of lamivudine is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and the specific indication. Dosage regimens are detailed in the product’s prescribing information and should not be altered without medical guidance.

Safety data for lamivudine in pregnancy are limited, and the drug is classified as pregnancy category unknown. Clinicians weigh potential benefits against risks. Breastfeeding is generally not recommended while on lamivudine unless the benefit to the mother outweighs potential infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for synergistic effect. Compared with agents like tenofovir, lamivudine has a favorable renal safety profile but may require combination with other drugs to achieve optimal viral suppression.

Lamivudine tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Do not store in humid or excessively hot environments, and keep out of reach of children.

Lamivudine is administered orally, usually as a tablet taken with or without food. The exact timing and whether it is taken once or twice daily depends on the prescribing regimen and the specific indication.

Serious risks include lactic acidosis, severe hepatotoxicity, pancreatitis, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if they occur.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is also advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnant women unless the potential benefit justifies the risk.